PMC8072150_01
Change in aPL levels before and after therapy. An extreme drop in aPL levels lasting for 4 days was observed after two sessions of plasmapheresis. aPS/PT IgM values even rose to higher levels than in baseline after plasmapheresis. One week after the first dose of daratumumab was administered, aCL IgG and aB2GPI IgG started a decline, this decline lasting until day +108. After day +108, a significant climb began. Levels of aPS/PT IgG lowered until day +248 and then went up again. Levels of aPS/PT IgM showed an intermittent up and down profile, but they have remained stable at half the titer of baseline from day +189 and onwards. PE, plasmapheresis; DARA, daratumumab.
fimmu-12-667515-g001.jpg
PMC8072150_01_fimmu-12-667515-g001.jpg
f1
Since then, aCL IgG, aB2GPI IgG and aPS/PT IgG began a smooth increase until the time of this report, with aPL values surpassing those from baseline ( Figure 1 ).